Abstract:The liver is a critical system for metabolism in human beings, which plays an essential role in an abundance of physiological processes and is vulnerable to endogenous or exogenous injuries. After the damage to the liver, a type of aberrant wound healing response known as liver fibrosis may happen, which can result in an excessive accumulation of extracellular matrix (ECM) and then cause cirrhosis or hepatocellular carcinoma (HCC), seriously endangering human health and causing a great economic burden. However, few effective anti-fibrotic medications are clinically available to treat liver fibrosis. The most efficient approach to liver fibrosis prevention and treatment currently is to eliminate its causes, but this approach’s efficiency is too slow, or some causes cannot be fully eliminated, which causes liver fibrosis to worsen. In cases of advanced fibrosis, the only available treatment is liver transplantation. Therefore, new treatments or therapeutic agents need to be explored to stop the further development of early liver fibrosis or to reverse the fibrosis process to achieve liver fibrosis resolution. Understanding the mechanisms that lead to the development of liver fibrosis is necessary to find new therapeutic targets and drugs. The complex process of liver fibrosis is regulated by a variety of cells and cytokines, among which hepatic stellate cells (HSCs) are the essential cells, and their continued activation will lead to further progression of liver fibrosis. It has been found that inhibiting HSC activation, or inducing apoptosis, and inactivating activated hepatic stellate cells (aHSCs) can reverse fibrosis and thus achieve liver fibrosis regression. Hence, this review will concentrate on how HSCs become activated during liver fibrosis, including intercellular interactions and related signaling pathways, as well as targeting HSCs or liver fibrosis signaling pathways to achieve the resolution of liver fibrosis. Finally, new therapeutic compounds targeting liver fibrosis are summarized to provide more options for the therapy of liver fibrosis.

Targeting Activated Hepatic Stellate Cells (ahscs) for Liver Fibrosis Imaging

Liver Fibrosis Therapy Based on Biomimetic Nanoparticles Which Deplete Activated Hepatic Stellate Cells.

Targeted Drug Delivery to Hepatic Stellate Cells for the Treatment of Liver Fibrosis

Regulatory Long Non-Coding RNAs of Hepatic Stellate Cells in Liver Fibrosis (Review)

Research on Receptor-Targeted Intervention and Regulation of Hepatic Stellate Cell Activation

Molecular Imaging of Hepatic Stellate Cell Activity by Visualization of Hepatic Integrin Αvβ3 Expression with SPECT in Rat

Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies

Platelet-derived Growth Factor Receptor Β-Targeted Positron Emission Tomography Imaging for the Noninvasive Monitoring of Liver Fibrosis.

Activation and Inhibition of Human HSCs and the Related Molecular Mechanisms

The Progression for the Therapy of Liver Fibrosis Targeting to Hepatic Stellate Cells

Hepatic stellate cells: a target for the treatment of liver fibrosis

An Integrin-Based Nanoparticle That Targets Activated Hepatic Stellate Cells and Alleviates Liver Fibrosis.

Therapeutic potential of targeting regulatory mechanisms of hepatic stellate cell activation in liver fibrosis

Molecular Magnetic Resonance Imaging of Activated Hepatic Stellate Cells with Ultrasmall Superparamagnetic Iron Oxide Targeting Integrin αvβ3 for Staging Liver Fibrosis in Rat Model

Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets

Intercellular crosstalk of hepatic stellate cells in liver fibrosis: New insights into therapy

Signal Transduction of Hepatic Stellate Cells in Liver Fibrosis

Molecular magnetic resonance imaging of activated hepatic stellate cells with ultrasmall superparamagnetic iron oxide targeting integrin αvβ3 for staging liver fibrosis in rat model

Hepatic Stellate Cell-Targeting Micelle Nanomedicine for Early Diagnosis and Treatment of Liver Fibrosis

Liver Fibrosis Resolution: from Molecular Mechanisms to Therapeutic Opportunities

Nano-encapsulation of drugs to target hepatic stellate cells: Toward precision treatments of liver fibrosis